Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: ken carney who wrote (146)	11/5/1997 6:30:00 PM
From: tdinovo	Read Replies (1) \| Respond to of 496

Ken, Normally, I could look at trade history for day and tell you more. Unfortunately, we were re-installing at a new location today and I have no data to examine. I noticed right at the open it was down a point and change and seemed to me to be under pressure throughout the day. I wouldn't be too unnerved. We're likely to see some sympathetic selling for next few days that is likely to drive price further. Nothing I could find studying SEC archives indicated news of significance. I think one of those toddler running a momentum fund (s) simply saw the earning down nominally (even though they exceeded expectations) and sold on the news. Frankly, stocks seem to act better without that crowd around. It's nice when they drive the stock wildly higher (based on reading tea leaves for all I know), but when they exit, they inevitably leave a big hole. I reiterate, once they're through, it should be a nice opportunity to buy. The company has a premier partner that needs their products bad and knows how to get molecules through the clinics and FDA. Relax, ignore the fireworks and a year or two from now, you'll have one on all those smart kids! Ted

To: ken carney who wrote (146)	11/6/1997 2:51:00 AM
From: John Dwyer	Read Replies (1) \| Respond to of 496

$1.5 million doesn't sound like a lot to me and fourth quarter sales are expected to be similar to third quarter sales. I think this paragraph likely contributed to the selloff... ''As a result of the third quarter sales of GLIADEL(R), our polymer product for brain cancer, Guilford received $1.5 million in revenues from our marketing partner Rhone-Poulenc Rorer, consisting of both product sales and royalties on end-user sales,'' continued Dr. Smith. ''For the fourth quarter, we anticipate slightly reduced product sales to RPR and increased royalties from end-user sales resulting in total GLIADEL(R)-related revenues similar to the amount received in the third quarter. Based on recent market research conducted by RPR, out of a total of approximately 20,000 surgeries per year for primary brain cancer, we currently estimate that there are approximately 2,500 to 3,500 patients annually in the U.S. eligible for the labeled indication (recurrent glioblastoma multiforme), and 5,000 to 7,000 patients annually who undergo initial surgery for malignant glioma.